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Hospitalization is common in patients with heart failure (HF) and is associated with high costs.1,2 Despite sub-
stantial progress in reducing mortality after HF diagnosis, 
rates of hospital admission remain high,3 and nearly 1 in 4 
HF patients is readmitted to hospital within 30 days of dis-
charge.4,5 Public and private payors have increasingly targeted 
readmissions for any reason as a focus of pay-for-performance 
incentives,6 stimulating increasing emphasis on measures to 
enhance the quality of care transitions and improve longitudi-
nal HF disease management.
Clinical Perspective on p 902
A large proportion of hospital admissions in HF patients 
is because of exacerbation of HF and related cardiovascular 
(CV) conditions, but more than half have been attributed to 
noncardiovascular (non-CV) causes.1 Although hospital-
ization for HF management is recognized to be associated 
with a high risk of subsequent mortality,7–9 the effect of non-
CV hospitalizations on subsequent prognosis is not as well 
described. We examined the incidence of mortality after first 
hospitalization for CV or non-CV reasons in a broad spec-
trum of HF patients enrolled in the Candesartan in Heart 
Failure: Assessment of Reduction in Mortality and Morbidity 
(CHARM) program.
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Background—Noncardiovascular (non-CV) comorbidities may contribute to hospitalizations in patients with heart failure 
(HF). We examined the incidence of mortality following hospitalization for cardiovascular (CV) versus non-CV reasons 
in the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.
Methods and Results—First hospitalizations for CV or non-CV reasons during the CHARM trial (N=7599) were related to 
subsequent risk of all-cause death using time-updated proportional hazards models. Over median 37.7 month follow-up, 
2816 subjects (37.1%) were not hospitalized, 2893 (38.1%) were first hospitalized for CV reasons, and 1890 (24.9%) for 
non-CV reasons. The death rate (per 100 patient-years) among those not hospitalized was 2.8 compared with 17.8 after CV 
and 16.5 after non-CV hospitalization (both P<0.001 versus not hospitalized). Mortality at 30 days was higher after CV 
than non-CV hospitalization; however, among 30-day survivors of CV and non-CV hospitalization, rates of subsequent 
mortality were similar (14.5 versus 14.6 per 100 patient-years; P=0.62). Rates of CV hospitalization were higher for those 
with ejection fraction (EF) ≤40% than those with EF >40% (P<0.001), but rates of non-CV hospitalization did not vary 
by EF. Low EF patients had higher risk for mortality than preserved EF patients after any hospitalization, but within each 
EF subgroup, mortality in 30-day survivors of CV versus non-CV hospitalization was similar.
Conclusions—Non-CV hospitalization is frequent in patients with symptomatic heart failure and associated with risk of 
subsequent mortality similar to CV hospitalization across the spectrum of EF. These findings may have implications for 
developing strategies to prevent readmissions.
Clinical Trial Registration—URL: http://www.clinicaltrials.gov. Unique identifier: NCT00634309 (CHARM-Added), 
NCT00634712 (CHARM-Preserved), NCT00634400 (CHARM-Alternative).  (Circ Heart Fail. 2014;7:895-902.)
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Methods
The CHARM Program
The design and main results of the CHARM Program have been previ-
ously reported.10–14 Briefly, CHARM consisted of 3-component random-
ized, double-blind, controlled trials comparing candesartan to placebo 
in 7599 subjects with symptomatic HF (New York Heart Association 
II-IV) treated with standard HF therapy. The CHARM-Alternative trial 
(http://www.clinicaltrials.gov, NCT 00634400) enrolled 2028 subjects 
with left ventricular ejection fraction (EF) ≤40% and previous intoler-
ance of angiotensin-converting enzyme–inhibitors with no requirement 
for prior hospitalization. The CHARM-Added (NCT 00634309) trial 
enrolled 2548 subjects with left ventricular EF ≤40% who were treated 
with an angiotensin-converting enzyme–inhibitor at baseline; to be 
eligible, those subjects with New York Heart Association II symptoms 
were required to have a CV hospitalization within 6 months before ran-
domization. The CHARM-Preserved trial (NCT 00634712) enrolled 
3023 subjects with left ventricular EF >40%, all of whom had a previ-
ous history of CV hospitalization. All participating sites obtained ap-
proval from local ethics committees or institutional review boards for 
the conduct of each of the 3-component trials, and all patients gave 
written informed consent before enrollment. The primary end point for 
the overall CHARM Program was all-cause mortality, whereas that for 
each of the component trials was the composite of CV death or HF 
hospitalization. The median follow-up duration for the overall trial was 
37.7 months.
Investigators were asked to report all elective and non-elective hos-
pitalizations during study follow-up and to assign the primary reason 
for each hospitalization to 1 of several predefined CV (worsening 
HF, hypotension, myocardial infarction, unstable angina, transient 
ischemic attack, stroke, atrial tachyarrhythmia, ventricular tachyar-
rhythmia, other) or non-CV (cancer, other) categories. The 8069 
hospitalizations assigned to the “other” categories contained free 
text descriptors of the primary cause that were individually reviewed 
by an experienced cardiologist (A.S. Desai) and used to design an 
algorithm reclassify the admission as possible into specific CV (as 
above) or non-CV categories (gastrointestinal, infectious, orthopedic/
rheumatologic, cancer, renal, pulmonary, endocrine, neurological/
psychiatric, urologic/gynecologic). The specific algorithm and pro-
gramming code used to perform the reclassification are provided in 
the Data Supplement.
Statistical Analysis
The proportion of first hospitalizations attributable to CV and 
non-CV causes was tabulated for the overall CHARM program. 
Hospitalizations carrying both CV and non-CV descriptors were as-
signed to the CV category. Subjects in whom the date of death co-
incided with the date of the hospitalization were classified as not 
hospitalized. Baseline characteristics for hospitalized and non-hos-
pitalized patients and for hospitalization by cause were compared us-
ing standard chi-squared tests for categorical variables and t tests for 
continuous variables.
Crude rates of all-cause mortality after first hospitalization for CV 
or non-CV reasons were compared in time-updated Cox proportion-
al hazards models.15 Adjusted hazard ratios for mortality were also 
generated after controlling for baseline predictors of all-cause mor-
tality identified in previous CHARM analyses.16 Because of the time- 
dependent risk of death associated with hospitalizations and viola-
tion of traditional proportional hazards assumptions, death rates were 
examined within 30 days of incident hospitalization and separately 
in 30-day survivors of hospitalization to discriminate the effect of 
nonfatal hospitalization events on subsequent prognosis. Analyses 
were replicated in subgroups with reduced (≤40%) and preserved 
(>40%) EF.
To assess the effect of cumulative CV and non-CV hospitalizations 
on subsequent prognosis, we compared death rates among the follow-
ing groups of patients according to their time-updated hospitalization 
status: those not hospitalized, those hospitalized once for CV or non-
CV reasons, and those with ≥2 hospitalizations during the trial. Death 
rates in those with ≥2 hospitalizations were calculated separately for 
those whose first 2 hospitalizations were both for CV reasons, those 
whose first 2 hospitalizations were both for non-CV reasons, and 
those with 1 hospitalization of each type.
All analyses were conducted using STATA statistical software 
(version 13, College Station, TX). The authors (A.S. Desai and B. 
Claggett) had full access to all the data in the study and take full 
responsibility for the integrity of the data and the accuracy of the 
data analysis.
Results
Hospitalizations in CHARM-Overall
Of 7599 subjects enrolled in the CHARM program, 2816 
(37.1%) were not hospitalized during the course of trial follow-
up. Of the remaining 4783 subjects with ≥1hospitalization, 
2893 (38.1%) were first hospitalized for CV reasons and 1890 
(24.9%) were first hospitalized for non-CV reasons. Among 
those first hospitalized for CV reasons, hospitalization for 
HF management accounted for 998 (34.5%), acute coronary 
syndromes for 556 (19.2%), arrhythmias for 263 (9.1%), and 
stroke/transient ischemic attack for 175 (6.0%). The most com-
monly reported specific non-CV causes of first hospitalization 
were pneumonia/respiratory tract infection, cancer, chronic 
obstructive pulmonary disease/bronchitis, cholelithiasis/biliary 
colic, renal failure, anemia, dizziness/vertigo, hyperkalemia, 
dehydration, and pancreatitis. In aggregate, gastrointestinal, 
infectious, and orthopedic/rheumatologic problems accounted 
for nearly half of the first non-CV hospitalizations (Figure 1).
Baseline characteristics according to type of first hospi-
talization are reported in Tables 1 and 2. Characteristics of 
the patients who died without hospitalization are separately 
reported in Table I in the Data Supplement. Hospitalized 
patients were older with more severe HF and more comorbidi-
ties than those who were not hospitalized (Table 1). Patients 
hospitalized first for CV reasons were similar to those hospi-
talized first for non-CV reasons, but were younger, had lower 
EF, and were more commonly men with a prior history of 
myocardial infarction and angina (Table 2).
Effect of First Hospitalization on Subsequent 
Mortality
The crude death rate (per 100 patient-years) among those 
not hospitalized was 2.8 (95% confidence interval [CI], 2.6–
3.1) compared with 17.8 (95% CI, 16.7–19.0) after first CV 
(relative risk [RR[, 6.3; 95% CI, 5.5–7.1; P<0.001) and 16.5 
(95% CI, 15.2–18.0) after first non-CV hospitalization (RR, 
5.8; 95% CI, 5.1–6.6). Mortality within the first 30 days was 
higher after CV than after non-CV hospitalization (90.4 [95% 
CI, 78.8–103.7] versus 55.9 [95% CI, 45.1–69.2] per 100 
patient-years; P<0.001); however, among 30-day survivors of 
CV and non-CV hospitalization, rates of subsequent mortality 
were similar (14.5 [95% CI, 13.4–15.6] versus 14.6 [95% CI, 
13.3–16.0] per 100 patient-years; P=0.85; Figure 1). The RR 
for death associated with first CV and non-CV hospitalization 
persisted after multivariable adjustment for baseline predic-
tors of mortality, including age, EF, diabetes mellitus, body 
mass index, New York Heart Association class, sex, smoking, 
prerandomization history of HF hospitalization, and treat-
ment assignment (adjusted hazard ratio [HR] 6.44 for CV 
[95% CI, 5.65–7.33], adjusted HR 6.14 for non-CV [95% CI, 
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5.33–7.08]). Further adjustment for country of origin did not 
substantively alter these findings (results not shown). Among 
those hospitalized for CV reasons, death rates were highest for 
those hospitalized for stroke (34.5 per 100 patient-years; 95% 
CI, 26.6–46.6), HF (28.6 per 100 patient-years; 95% CI, 26.1–
33.3), and myocardial infarction (25.6 per 100 patient-years; 
95% CI, 19.9–32.9); among those first hospitalized for non-
CV reasons, death rates were highest for cancer (43.9 per 100 
patient-years; 95% CI, 34.7–55.5), pulmonary disease (23.3 
per 100 patient-years; 95% CI, 17.5–31.0), and renal disease 
(21.2 per 100 patient-years; 95% CI, 16.0–28.1; Figure 1).
First Hospitalization in Preserved Versus Reduced 
EF Subgroups
The incidence of first hospitalization for CV reasons was higher 
in patients with EF ≤40% than those with EF >40% (23.6 versus 
19.3 per 100 patient-years; P<0.001), but the incidence of non-
CV hospitalization was similar in both EF subgroups (Table 3). 
Accordingly, the proportion of first hospitalizations related to 
non-CV reasons was highest in patients with preserved EF and 
declined with lower EF (Figure 2). Among those first hospital-
ized for CV reasons, the proportion hospitalized for HF was lower 
in patients with HF and preserved EF than in those with HF and 
reduced EF (26.8% versus 38.9%; P<0.001). Low EF patients 
were at higher risk for mortality than high EF patients whether 
not hospitalized (3.8 versus 1.5 per 100 patient-years; P<0.001; 
RR=2.6; 95% CI, 1.99–3.27), after CV hospitalization (21.9 ver-
sus 11.4 per 100 patient-years; P<0.001; RR=1.93; 95% CI, 1.66–
2.24; adjusted HR, 1.85; 95% CI, 1.59–2.17), or after non-CV 
hospitalization (19.4 versus 12.6 per 100 patient-years; P<0.001; 
RR=1.54; 95% CI, 1.28–1.84; adjusted HR, 1.42; 95% CI, 1.17–
1.73). However, as for the population as a whole, mortality rates 
among 30-day survivors of CV and non-CV hospitalization were 
similar in both EF subgroups (17.6 versus 17.3 per 100 patient-
years, P=0.77 for EF ≤40%; 9.6 versus 11.0 per 100 patient-years, 
P=0.22 for EF >40%; Table 3). Similar results were apparent in 
sensitivity analyses restricted to the subset of patients with a his-
tory of HF hospitalization before enrollment in the trial, the subset 
of CHARM-preserved patients with EF >50%, and the subset of 
CHARM low EF subjects treated with an angiotensin-converting 
enzyme–inhibitor and β-blocker at baseline (Tables II–IV in the 
Data Supplement).
Cumulative Hospitalizations
During the course of trial follow-up, a cumulative total of 14 740 
hospitalizations was recorded in CHARM, including 8965 
(60.8%) for CV reasons and 5775 (39.2%) for non-CV reasons. 
Relative to placebo, treatment with candesartan was associated 
Figure 1. First hospitalizations according to cause and subsequent mortality, Candesartan in Heart Failure: Assessment of Reduction in 
Mortality and Morbidity (CHARM)-Overall. CV indicates cardiovascular; GI, gastrointestinal; HF, heart failure; MI, myocardial infarction; 
and TIA, transient ischemic attack. 
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with a reduction in total hospitalizations and in the proportion 
of hospitalizations because of CV reasons (58.6% versus 62.9% 
for candesartan versus Placebo; P<0.001), but treatment did 
not influence the risk of death after first hospitalization (HR, 
0.93; 95% CI, 0.84–1.03; P=0.146). The detailed breakdown of 
patients by first and subsequent hospitalization status is reported 
in Figure 3. Death rates among those hospitalized once for CV 
reasons were higher than those hospitalized once for non-CV 
reasons. However, among those with ≥2 hospitalizations, death 
rates were similar for those whose first 2 hospitalizations were 
for CV reasons, those whose first 2 hospitalizations were for 
non-CV reasons, and those with 1 of each type (Figure 3).
Discussion
In this population of symptomatic HF patients across broad 
range of EFs, nearly a third of whom were previously hospi-
talized for HF exacerbation, we found that non-CV reasons 
accounted for nearly 40% of first hospital admissions. The 
incidence of non-CV hospitalization was nearly constant 
across EF categories, whereas that of CV hospitalization 
declined with increasing EF; accordingly, the proportion 
of total admissions attributable to non-CV causes increased 
with EF. Although the CHARM trial systematically enrolled 
patients with symptomatic HF, the minority of CV hos-
pitalizations during trial follow-up were related to HF 
Table 1. Baseline Characteristics, CHARM-Overall, According to Incident Hospitalization During Follow-Up
Any Hospitalization 
(N=4783, 62.9%)
Not Hospitalized 
or Death Without 
Hospitalization  
(N=2816, 37.1%)
P Value  
(Hospitalization vs 
No Hospitalization)
Patients’ characteristics
  Age, y, mean (SD) 66.7 (11.0) 63.9 (10.9) <0.0001
   ≥75 1284 (26.8%) 452 (16.1%) <0.0001
  Men 3260 (68.2%) 1939 (68.9%) 0.54
Heart disease risk factors
  NYHA class <0.0001
   II 1929 (40.3%) 1487 (52.8%)
   III 2698 (56.4%) 1287 (45.7%)
   IV 156 (3.3%) 42 (1.5%)
  LVEF, %, mean (SD) 38.4 (15.1) 39.7 (14.5) <0.0001
   <30 1443 (30.2%) 674 (23.9%)
   ≥30–39 1355 (28.3%) 851 (30.2%)
   ≥40–49 767 (16.0%) 555 (19.7%)
   ≥50 1217 (25.4%) 736 (26.1%)
  Heart rate, beats/min, mean (SD) 73.2 (13.1) 72.4 (13.0) 0.008
  Blood pressure, mm Hg, mean (SD)
   Systolic 130.3 (19.4) 131.8 (18.7) 0.001
   Diastolic 75.7 (10.8) 78.3 (10.5) <0.0001
  Body mass index, kg/m2, mean (SD) 28.2 (5.6) 28.3 (5.2) 0.09
Medical history
  Prior hospital admission for CHF 3557 (74.4%) 1869 (66.4%) <0.0001
  Myocardial infarction 2595 (54.2%) 1409 (50.0%) 0.0004
  Current angina 1223 (25.6%) 585 (20.8%) <0.0001
  Stroke 484 (10.1%) 179 (6.4%) <0.0001
  Diabetes mellitus 1526 (31.9%) 637 (22.6%) <0.0001
  Hypertension 2691 (56.3%) 1495 (53.1%) 0.008
  Atrial fibrillation 1468 (30.7%) 615 (21.8%) <0.0001
  Pacemaker 486 (10.2%) 151 (5.4%) <0.0001
  Current smoker 697 (14.6%) 417 (14.8%) 0.79
  PCI 825 (17.2%) 403 (14.3%) 0.0008
  CABG 1222 (25.6%) 569 (20.2%) <0.0001
  Implantable cardioverter defibrillator 148 (3.1%) 43 (1.5%) <0.0001
  Previous cancer 366 (7.6%) 147 (5.2%) <0.0001
CABG indicates coronary artery bypass graft; CHARM,  Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; 
CHF, chronic heart failure; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and PCI, percutaneous coronary 
intervention.
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exacerbation. Hospitalization for any reason was associated 
with high risk for subsequent mortality, with higher risk in 
low than preserved EF patients. Early mortality was higher 
after first CV than first non-CV hospitalization, but rates of 
mortality in 30-day survivors were similar in both groups. 
Cumulative hospitalizations increased the risk of death, but 
death rates were similar in patients with ≥2 CV hospitaliza-
tions, ≥2 non-CV hospitalizations, and those with ≥1 of each 
type.
Non-CV comorbidities, including chronic obstructive pul-
monary disease, chronic kidney disease, diabetes mellitus, 
depression, and dementia, are common in patients with HF 
and frequently precipitate, contribute to, or complicate HF 
exacerbation and the need for hospital admission.17–21 The bur-
den of comorbidities seems to be closely linked to the risk 
for hospital admission, particularly in the elderly and in those 
with preserved EF,20,22 and is an important driver of healthcare 
costs.23,24 In a cross-sectional analysis of 122 630 Medicare 
patients with HF over the age of 65 years, >80% of the total 
inpatient hospital days during follow-up were accounted for 
by the 40% of subjects with ≥5 noncardiac comorbidities.20 
Our data confirms and extends previous data from published 
registries,25 randomized trials,26–28 and community dwell-
ing populations,1 highlighting the substantial contribution of 
non-CV hospitalization to the overall burden of hospitaliza-
tion in HF patients. Notably, patients hospitalized for non-CV 
Table 2. Baseline Characteristics, CHARM-Overall, According to Reason for First Hospitalization
First Hospitalization for  
CV Reasons (N=2893, 38.1%)
First Hospitalization for 
Non-CV Reasons  
(N=1890, 24.9%)
P Value  
(CV vs Non-CV)
Patients’ characteristics
  Age, y, mean (SD) 66.8 (10.9) 67.8 (11.0) 0.004
   ≥75 760 (26.3%) 524 (27.7%) 0.27
  Men 2030 (70.2%) 1230 (65.1%) 0.0002
Heart-disease risk factors
  NYHA class 0.21
   II 1161 (40.1%) 768 (40.6%)
   III 1627 (56.2%) 1071 (56.7%)
   IV 105 (3.6%) 51 (2.7%)
  LVEF, %, mean (SD) 37.6 (15.0) 39.5 (15.2) <0.0001
   <30 926 (32.0%) 517 (27.4%)
   ≥30–39 838 (29.0%) 517 (27.4%)
   ≥40–49 422 (14.6%) 345 (18.3%)
   ≥50 706 (24.4%) 511 (27.0%)
  Heart rate, beats/min, mean (SD) 73.1 (13.4) 73.3 (12.6) 0.27
  Blood pressure, mm Hg, mean (SD)
   Systolic 129.8 (19.3) 131.1 (19.5) 0.03
   Diastolic 75.6 (10.8) 75.8 (10.8) 0.47
  Body mass index, kg/m2, mean (SD) 28.1 (5.4) 28.4 (5.9) 0.12
Medical history
  Prior Hospital admission for CHF 2144 (74.1%) 1413 (74.8%) 0.61
  Myocardial infarction 1650 (57.0%) 945 (50.0%) <0.0001
  Current angina 817 (28.2%) 406 (21.5%) <0.0001
  Stroke 300 (10.4%) 184 (9.7%) 0.49
  Diabetes mellitus 917 (31.7%) 609 (32.2%) 0.70
  Hypertension 1623 (56.1%) 1068 (56.5%) 0.79
  Atrial fibrillation 862 (29.8%) 606 (32.1%) 0.10
  Pacemaker 307 (10.6%) 179 (9.5%) 0.20
  Current smoker 421 (14.6%) 276 (14.6%) 0.97
  PCI 525 (18.2%) 300 (15.9%) 0.04
  CABG 755 (26.1%) 467 (24.7%) 0.29
  Implantable cardioverter defibrillator 92 (3.2%) 56 (3.0%) 0.73
  Previous cancer 200 (6.9%) 166 (8.8%) 0.02
CABG indicates coronary artery bypass graft; CHARM,  Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; 
CHF, chronic heart failure; CV, cardiovascular; LVEF, left ventricular ejection fraction; NYHA, New York Heart Association; and PCI, percutaneous 
coronary intervention.
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reasons were not easily distinguished from those hospitalized 
for CV reasons by their demographic or clinical characteris-
tics. As well, these analyses underscore the greater propor-
tionate contribution of non-CV hospitalization to morbidity in 
those with HF and preserved EF, for whom noncardiac illness 
may be a particularly important target for therapy.22,29
Although unplanned hospitalization for HF management 
is known to be an important predictor of the risk for subse-
quent mortality both in CHARM8 and in other populations,7 
these hospitalizations accounted for fewer than one hird of 
total hospitalizations recorded during the period of trial fol-
low-up in CHARM. Our analysis is novel in its focus on the 
prognostic relevance of the balance of non-HF–related hos-
pitalization events. That hospitalization for CV reasons more 
generally is associated with poor prognosis, particularly in 
the early postdischarge interval, is less surprising than the 
finding that 30-day survivors of non-CV and CV hospitaliza-
tion have similar rates of subsequent death. There are several 
potential explanations for the risk associated with non-CV 
hospitalization in HF patients. First, the need for hospitaliza-
tion to manage non-CV issues may mark patients with a larger 
overall burden and severity of medical illness that is itself 
associated with risk for death in HF patients. Second, exacer-
bations of comorbidities, such as obstructive lung disease and 
chronic kidney disease, may directly contribute to worsening 
HF severity and compromise subsequent outcomes. Finally, 
patients with a large burden of comorbidities may be less able 
to tolerate optimal HF treatement or experience difficulties 
with adherence to the prescribed medical program.
Whatever the specific explanation, the finding that hospitaliza-
tion for any cause has similar prognostic relevance in HF patients 
should draw attention from those interested in improving the qual-
ity and reducing the overall costs associated with HF care. To date, 
most HF disease management strategies have heavily emphasized 
appropriate application of guideline-directed medical therapies and 
aggressive management of filling pressures to relieve congestive 
symptoms and improve outcomes. Although these strategies are 
undoubtedly important, such intensive focus on refining the man-
agement of a single severe, chronic medical condition may detract 
from attention to seemingly unrelated conditions that can also 
powerfully affect subsequent outcomes.30 Available data suggests 
that many non-CV admissions may be related to ambulatory care–
sensitive conditions and are therefore potentially preventable.20 In 
this context, inadvertent neglect of comorbid medical illness in HF 
patients may represent a missed-opportunity for reducing hospital 
admissions and improving HF care.19
Our analysis must be viewed in the context of its limitations. 
First, we focused on the effect of the first admission during 
follow-up in CHARM on subsequent prognosis. Because many 
patients had both CV and non-CV admissions over the course 
of trial follow-up, this analysis may be vulnerable to overstat-
ing the effect of non-CV admissions on subsequent mortality. 
However, similar results in the time-varying models exploring 
the effect of cumulative rates of CV and non-CV hospitalization 
suggest that our findings regarding the prognostic relevance of 
non-CV hospitalization are robust. Second, like all clinical trial 
populations, patients in CHARM represent a selected population 
of HF patients, including some previously hospitalized for CV 
reasons; accordingly, these results may not be generalizable to 
community HF populations with no prior experience of hospi-
talization. Finally, because we identified the primary reason for 
hospitalization based on investigator report, we cannot exclude 
the possibility that some CV hospitalizations may have been 
misclassified as non-CV and vice-versa. Although some may 
challenge our algorithm for categorizing CV and non-CV hospi-
talization (see appendix), comparable rates of CV and non-CV 
hospitalization reported here from CHARM to those previously 
Figure 2. Incidence of first hospitalizations for cardiovascular 
(CV) and Non-CV Reasons, by ejection fraction.
Table 3. Incidence of Death After First CV or Non-CV Hospitalization, CHARM Overall, and EF Subgroups
LVEF ≤40% (N=4576) LVEF >40% (N=3023)
First Hospitalization  
for CV Reasons
First Hospitalization for  
Non-CV Reasons
First Hospitalization  
for CV Reasons
First Hospitalization 
for Non-CV Reasons
Proportion hospitalized 1842 (40.2%) 1112 (24.3%) 1051 (34.8%) 778 (25.7%)
Incidence of hospitalization  
(per 100 patient-years)
23.6 (22.6, 24.7) 14.3 (13.5, 15.2) 19.3 (18.2, 20.5) 14.3 (13.3, 15.3)
Deaths within 30 days of hospitalization 160/1842 (8.7%) 55/1112 (5.0%) 44/1040 (4.2%) 29/778 (3.7%)
Incidence of death within 30 days  
(per 100 patient-years)
112.4 (96.3, 131.3) 62.4 (47.9, 81.3) 52.8 (39.3, 70.9) 46.6 (32.4, 67.1)
Deaths in 30-day survivors 528/1671 (31.6%) 312/1043 (29.9%) 185/1000 (18.5%) 142/742 (19.1%)
Incidence of death after 30 day window (per 100 
patient-years)
17.6 (16.2, 19.2) 17.3 (15.5, 19.3) 9.6 (8.3, 11.1) 11.0 (9.3, 12.9)
CHARM indicates Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity; CV, cardiovascular; and LVEF, left ventricular ejection 
fraction.
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reported in other HF populations argue against any systematic 
error in category assignment.
In summary, we found that a substantial portion of the morbid-
ity and risk of mortality in patients with HF is related to non-CV 
hospitalizations. These findings suggest the need for approaches 
to HF disease management that focus more comprehensively on 
the treatment of both CV and non-CV comorbidities, rather than 
exclusively on HF management.31 Though the optimal model for 
care delivery has yet to be defined, there is increasing evidence 
to support strategies that leverage the combined expertise of both 
primary care providers and CV experts.32 Embedding HF disease 
management within integrated care delivery models, such as the 
patient-centered medical home, may be an important step to mak-
ing a sustained effect on HF readmission rates.
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CLINICAL PERSPECTIVE
Although many hospital admissions in heart failure patients are caused by exacerbation of heart failure and related cardiovas-
cular (CV) conditions, a large proportion are related to noncardiovascular (non-CV) causes. Hospitalization for heart failure 
management is known to be associated with high risk for subsequent mortality, but the prognostic implications of non-CV 
hospitalizations in patients with chronic heart failure are less clear. In this analysis from the CHARM Program, we highlight 
the important contribution of non-CV hospitalization to morbidity and the risk of mortality in heart failure patients across 
the spectrum of ejection fraction. Non-CV hospitalization accounted for nearly 40% of first hospitalizations during the trial, 
and the proportion of total admissions attributable to non-CV causes increased with ejection fraction. Hospitalization for 
any reason was associated with high risk for subsequent mortality, with similar death rates in 30-day survivors of both CV 
and non-CV hospitalization. By underscoring the prognostic importance of non-CV hospitalization, these data suggest the 
need for approaches to heart failure disease management that focus more comprehensively on the treatment of both CV and 
non-CV comorbidities, rather than exclusively on heart failure management. As well, because many non-CV hospitalizations 
may be related to ambulatory care–sensitive conditions, our findings suggest potential to reduce rates of hospital readmission 
in heart failure patients through greater attention to management of comorbid medical illness.
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SUPPLEMENTARY METHODS 
METHODOLOGY FOR CLASSIFICATION OF HOSPITALIZATIONS IN CHARM 
CHARM Investigators were asked to report all elective and non-elective hospitalizations during study 
follow up and to assign the primary reason for each hospitalization to one of several predefined CV 
(worsening HF, hypotension, myocardial infarction, unstable angina, transient ischemic attack, stroke, 
atrial tachyarrhythmia, ventricular tachyarrhythmia, other) or non-CV (cancer, other) categories.  8069 
hospitalizations assigned to the ‘other’ categories contained free text descriptors of the primary cause. 
On review by an experienced cardiologist (ASD) of the ‘other CV’ and ‘Other non-CV’ hospitalization 
descriptors, it was clear that a number of events were likely ‘misclassified’. We individually reviewed the 
descriptors for these events to identify a series of free text search strings associated clearly with 
identifiable ‘CV’ and  ‘non-CV’ causes of hospitalization.  
The following search strings were identified as descriptors for ‘CV’ hospitalizations amongst the non-CV 
category (spelling variations are deliberate):  
ischem, ischaem, vascu, arter, ptca, endar, claud, angio, digoxin, digitalis, amioda, angina, aort, ICD, 
HF, warfa, couma, anticoag, coagul, tachyc, bradyc, tachybrady, hypert, thrombo, atria, afib, defib, 
bypass, buerg, a-v block, cardiac, carduac, cardio, cordis, heart, gangren, amputat, phelibitis, 
pacemaker, pace maker, pci, blood clot, DVT, PAD, CAD, IHD, embolism, heart transplan, heart 
failure, palpitation, mitral, carotid, myocardial, iliac, pericard, poplitea, varicos, ablation, INR, bypass 
op, by pass op, aneurysm, arrythmia, arrhyth, digitoxicity, electrophysiology, arteriovenous, 
artenovenous, hypotension, atrio-ventricular, atroventricular, sotalol, beta-blocker, embolectomy, 
tromboplebitis, trombosis, mesenteric, mesentric, phlebitis, dissociatio AV, vascular op, sick sinus, 
sinus sick, carotis, atypical c.p, digital infarc, fainting, insufficient circu, peripheral circ, peripheral 
occlus, volume overload, syncop, synkop, collap, chest pain, chestpain, chest-pain, chest wall pain, 
thoracal, thoracic, toracic, precordial, chest tight, shortness of breath, s.o.b., dyspn, cabg, coronary, 
3 
 
pulmonary oed, pulmonary ed, subarac, cerebral infarc, venous inuf, planned pta, ganglia 
In addition the following search strings were used to identify non-CV events from the CV category 
(spelling variations are deliberate):  
(Infectious) sepsis, pneumonia, infect, UTI, absces, cellul, endocarditis, septic, erysi, erisi, empy, 
pyel, pyoderma, cysti, viral, herpes, HIV, AIDS, fever, abcess, angitis, influ, osteomyelitis, febrile, 
bacter, celllu, clostridium, cholangoitis, purulent  
(Endocrine) diab, DM, glyc, glicae, glace, ycae, gluc, thyr, calci, calcemia, iddm, insuli, addison, 
goitre,goiter 
(Pulmonary) lung, pulmo, bronch, copd, chronic obstructive, respiratory, cough, apn, pulmonary 
fibrosis, pleural effusion, pleuritis, pleura, emphysema, pneumothorax, emoptysis, hyperventilation, 
asthma, COAD, COPD, C.O.P.D., pneumopat, dispnoe, hypoxia, chronic airways, hydrothorax, 
hemothorax, hemophtysis, hemoptoea 
(Orthopedic/Rheum) gout, arhtrit, arthra, artri, atrit, gatrit, fract, elbow, arthro, hip, lipis, ortho, 
skelet, rheum, joint, knee, spine, lamin, verteb, rhabdo, spondy, disc, discom, disk, lumba, femur, 
carpal, karpal, sarcoid, sarkoid, wegeners, polymyosit, osteitis 
(Oncologic) cancer, tumor, carci, leukem,leukaem, polycythemia, polycythaemia, monoclonal, 
myeldysplas, neutropenia, lymphoma, melanoma, clauvicular mass 
(Gastrointestinal) abdomin, abdomen, stomac, emesis, intest, digest, pancea, ulcer, ulcus, colic, 
colon, nausea, rectal, constip, obstip, append, ileus, gastr, gatrit, GI bleed, G-I, melena, melaena, 
hematemesis, chole, cholitis, diar, pancreatitis, colitis, hepatitis, bowel, duodenitis, dyspep, dyspetic, 
ercp, gerd, dysphagia, hemorr, haemorr, hernia, hepatic, liver, gall, anus, anal, spleen, appendix, 
vomit, phagitis, cecum, caecum, jaundice, divertic, divestic, varices, colost, haemirroid, volvul, ascit, 
polypec, polipec, acsitis, ileitis, ilieus, bilary, biliary, GI, G.I, cirrosis, cirrhosis, rectum, hepato, 
4 
 
enteritis, colectomy, bile, rectosigm, coloscop, oesophagus, hematemisis, haematomesis, 
hematochezia, peritonitis, duoden, ascitis, rectocele, oesophagectomy 
(Genitourinary) hematuria, haematuria, prosta, urine, urinere, urina, urolith, ureth, urolog, ureter, 
vagin, gynaeco, hyster, ovar, uterin, metrorrha, bladder, ophor, hydrocele, epidydim, epididim, 
endometri, epididymitis 
(Renal) renal, ranal, kalemia, kaliem, kalaem, kaliamia, kaliaem, kidney, natremia, hyponat, potass, 
hyperpot, hypovol, azotemia, uremia, uraemia, uramia, electrolyte, neph, dialysis, dehyd, hypo na, 
hypokalemia, tubular 
(Neurologic) seizure, guillain, headache, migra, dizz, vertigo, parkins, numbness, amnesia, depress, 
psychosis, halluc, anxie, ataxia, vestib, palsy, epilep, enceph, confus, dement, cerebr, subdur, mental, 
neuro, alzh, alzei, giddi, subsarach, manic, paranoia, coma, myotonic, paresthesia, radiculop, 
myelopath, deliri, panic, sciatica, walking impaired, aphasia, neuralgia, convulsions, delerium, 
dilantin, gait, autonomy 
(Other Non-CV) general, alco, alchol, sleep, stress, weight, intox, retina, epistax, catara, accident, 
trauma, alko, anaemia, operation, rehab, unknown, fall, social, fatigue, weakness, malaise, elective, 
anorexia, etoh, cocaine, suicid, failure to thr, failure to tr, narcotic, myalgia,lipothymia, eczema, 
obesity, psoriasis, vitrectomy, dental, haematoma, wound, nose, hemoptic, rash, tinni, cheloid 
hypertrophy  
The following decision rules were then applied: 
a.      For hospitalizations initially classified as "Other CV", the classification was changed to non-CV only 
if: a) none of the CV search terms were detected, and b) at least one non-CV search term was 
detected. For hospitalizations initially classified as "Other non-CV", the classification was changed to 
5 
 
CV only if: a) none of the non-CV search terms were detected, and b) at least one CV search term 
was detected. 
b.      Events with both CV and non-CV descriptors were assigned to the CV category 
c.       All admissions for chest pain, unless clearly designated ‘non-cardiac’ were conservatively assigned 
to the CV category 
d.      Where possible, CV and non-CV events were assigned to specific CV (worsening HF, hypotension, 
myocardial infarction, unstable angina, transient ischemic attack, stroke, atrial tachyarrhythmia, 
ventricular tachyarrhythmia, other) and non-CV (gastrointestinal, infectious, 
orthopedic/rheumatologic, cancer, renal, pulmonary, endocrine, neurologic/psychiatric, 
urologic/gynecologic) categories. Events were assigned to non-CV categories in a hierarchical 
fashion to help guide the unique assignment of events that could be allocated to more than one non-
CV category. 
All events reclassified by this methodology were reviewed by a single investigator (ASD) for errors in 
category assignment. 
Events that were not reclassified were again reviewed to ensure that they could not be assigned to a more 
specific CV or non-CV category. 
The specific programming code used to perform the reclassification is available on request.  
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Supplementary Table 1. Baseline Characteristics, CHARM-Overall, according to incident hospitalization during follow up (separating 
those who died without hospitalization) 
 Any Hospitalization 
(N=4783, 62.9%) 
 Not Hospitalized (N=2816, 37.1%)  
  Alive, Not  
Hospitalized 
(N=2440, 32.1%) 
Died without 
Hospitalization 
(N=376, 4.9%) 
p-value 
(hosp vs. no hosp) 
Patients’ characteristics     
Mean (SD) age (years) 66.70 ± 10.96 62.86 ± 10.84 66.85 ± 10.62 < 0.001 
  ≥75 years 1284    (26.8%) 355    (14.5%) 98     (26.1%) < 0.001 
Men  3260    (68.2%) 1651    (67.7%) 288    (76.6%) 0.002 
Heart-disease risk factors     
NYHA class    < 0.001 
   II 1929    (40.3%) 1374    (56.3%) 113    (30.1%)  
   III 2698    (56.4%) 1041    (42.7%) 246    (65.4%)  
   IV 156    (3.3%) 25     (1.0%) 17     (4.5%) 
Mean (SD) LVEF (%) 38.38 ± 15.10 40.83 ± 14.25 32.03 ± 13.46 < 0.001 
EF Categories    < 0.001 
   <30 1443    (30.2%) 501    (20.5%) 173    (46.0%)  
   ≥30-39 1355    (28.3%) 740    (30.3%) 111    (29.5%)  
   ≥40-49 767    (16.0%) 510    (20.9%) 45     (12.0%)  
   ≥50 1217    (25.4%) 689    (28.2%) 47     (12.5%) 
Mean (SD) heart rate (beats/min) 73.18 ± 13.07 72.05 ± 13.02 74.35 ± 12.73 <0.001 
Mean (SD) blood pressure(mm Hg)    
   Systolic 130.30 ± 19.41 132.56 ± 18.68 127.11 ± 18.22 < 0.001 
   Diastolic 75.66 ± 10.80 78.73 ± 10.40 75.45 ± 10.93 < 0.001 
Mean (SD) body-mass index (kg/m2) 28.21 ± 5.58 28.49 ± 5.21 27.35 ± 4.96 < 0.001 
Medical history     
Prior Hospital admission for CHF 3557    (74.4%) 1598    (65.5%) 271    (72.1%) < 0.001 
Myocardial infarction 2595    (54.3%) 1179    (48.3%) 230    (61.2%) < 0.001 
Current angina 1223    (25.6%) 500    (20.5%) 85     (22.6%) < 0.001 
Stroke 484    (10.1%) 143    (5.9%) 36     (9.6%) < 0.001 
Diabetes mellitus 1526    (31.9%) 508    (20.8%) 129    (34.3%) < 0.001 
Hypertension 2691    (56.3%) 1293    (53.0%) 202    (53.7%) 0.026 
Atrial fibrillation 1468    (30.7%) 502    (20.6%) 113    (30.1%) < 0.001 
Pacemaker 486    (10.2%) 116    (4.8%) 35     (9.3%) < 0.001 
Current smoker 697    (14.6%) 355    (14.5%) 62     (16.5%) 0.59 
PCI 825    (17.2%) 366    (15.0%) 37     (9.8%) < 0.001 
CABG 1222    (25.5%) 486    (19.9%) 83     (22.1%) < 0.001 
Implantable cardioverter defibrillator 148    (3.1%) 39     (1.6%) 4      (1.1%) < 0.001 
Previous cancer 366    (7.7%) 126    (5.2%) 21     (5.6%) < 0.001
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Supplementary Table 2. Incidence of Death after first CV or non-CV hospitalization, CHARM overall and EF subgroups, patients with 
HF hospitalization prior to randomization 
 
Supplementary Table 3. Incidence of Death after first CV or non-CV hospitalization, CHARM EF subgroups 
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Supplementary Table 4. Incidence of Death after first CV or non-CV hospitalization, CHARM EF subgroups, including those treated 
with ACE-inhibitor/beta-blocker at baseline 
 
 
 
